ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 41328353

FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities.

Xu J and 4 others. Theranostics, 2026. Cited by 5 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities. Papers, record 41328353. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41328353

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities.
PubMed
Journal
Theranostics
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
2.84, provisional
iCite
Revised in PubMed
2026-08-20
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xu JJiayi
2Sun PPeng
3Zhu WWenjing
4Liu XXinlin
5Ma LLeina

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Fibroblast Growth FactorsMajor topic
NeoplasmsMajor topic
Humans
Animals
Receptor, Fibroblast Growth Factor, Type 4
Signal Transduction
Tumor Microenvironment
Epithelial-Mesenchymal Transition
Molecular Targeted Therapy
Metabolic Reprogramming

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References363

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138,689,741Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept.World J Hepatol2024https://conductscience.org/library/papers/38689741PubMed
239,575,660Clinical and Genomic Phenotype of Brain Metastasis in Nasopharyngeal Carcinoma.Mol Carcinog2025https://conductscience.org/library/papers/39575660PubMed
311,276,432Fibroblast growth factors.Genome Biol2001https://conductscience.org/library/papers/11276432PubMed
437,976,704Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges.Eur J Med Chem2024https://conductscience.org/library/papers/37976704PubMed
538,997,257Glucose-6-phosphate dehydrogenase maintains redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer.Nat Commun2024https://conductscience.org/library/papers/38997257PubMed
637,732,990A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.Hepatology2024https://conductscience.org/library/papers/37732990PubMed
727,192,118Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.Oncotarget2016https://conductscience.org/library/papers/27192118PubMed
833,754,043FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.Theranostics2021https://conductscience.org/library/papers/33754043PubMed
935,484,633Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.Acta Neuropathol Commun2022https://conductscience.org/library/papers/35484633PubMed
1036,604,721FGF23 promotes proliferation, migration and invasion by regulating miR-340-5p in osteosarcoma.J Orthop Surg Res2023https://conductscience.org/library/papers/36604721PubMed

1 to 10 of 363

See all 363 references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42,581,056
Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole-curcumin nanocomplex through TLR2-FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer.
Sci Rep2026https://conductscience.org/library/papers/42581056PubMed
42,443,944Causal immune-inflammation mapping of the GERD-Barrett-adenocarcinoma cascade identifies FGF19-HLA-DR⁺ T-cell axis driving esophagogastric junction metaplasia.J Transl Med2026https://conductscience.org/library/papers/42443944PubMed
41,992,238The evolving role of OMICS in gastrointestinal tumor biology and clinical practice.Mol Cancer2026https://conductscience.org/library/papers/41992238PubMed
41,221,272Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells.Front Immunol2025https://conductscience.org/library/papers/41221272PubMed

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FGF199,965PubTator's text mininghttps://conductscience.org/library/genes/9965NCBI Gene
FGFR42,264PubTator's text mininghttps://conductscience.org/library/genes/2264NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41328353

GET https://conductscience.org/api/papers/v1/41328353/references?page=2

API referenceFor AI assistants